Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis

Yasushi Ino, Rebecca Betensky, Magdalena C. Zlatescu, Hikaru Sasaki, David R. Macdonald, Anat O. Stemmer-Rachamimov, David A. Ramsay, J. Gregory Cairncross, David N. Louis

Research output: Contribution to journalArticle

Abstract

Purpose: In a prior study of anaplastic oligodendrogliomas treated with chemotherapy at diagnosis or at recurrence after radiotherapy, allelic loss of chromosome 1p correlated with better chemotherapeutic response and overall survival. However, in this group of patients in whom therapeutic management was not uniform, loss of 1p did not identify all chemosensitive tumors, nor did all patients whose tumors harbor a 1p loss have long survival. Experimental Design: To clarify the clinical relevance of molecular genetic testing at the time of diagnosis for patients with anaplastic oligodendrogliomas, we studied a larger, more homogeneous group of 50 patients with histologically defined anaplastic oligodendrogliomas treated with a chemotherapeutic regimen as the principal initial therapy. Results: We demonstrate that these tumors can be divided genetically into four therapeutically and prognostically relevant subgroups. Patients whose tumors have combined but isolated losses of 1p and 19q have marked and durable responses to chemotherapy associated with long survival, with or without postoperative radiation therapy. Other tumors with chromosome 1p alterations also respond to chemotherapy, but with shorter duration of response and patient survival. Tumors lacking 1p loss can also be divided into two subgroups: those with TP53 mutations, which may also respond to chemotherapy but recur quickly, and those without TP53 mutations, which are poorly responsive, aggressive tumors that are clinically and genotypically similar to glioblastomas. Conclusions: These data raise the possibility, for the first time, that therapeutic decisions at the time of diagnosis might be tailored to particular genetic subtypes of anaplastic oligodendroglioma.

Original languageEnglish (US)
Pages (from-to)839-845
Number of pages7
JournalClinical Cancer Research
Volume7
Issue number4
StatePublished - Jan 1 2001

Fingerprint

Oligodendroglioma
Neoplasms
Drug Therapy
Survival
Radiotherapy
Chromosomes
Mutation
Loss of Heterozygosity
Genetic Testing
Glioblastoma
Molecular Biology
Research Design
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ino, Y., Betensky, R., Zlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., ... Louis, D. N. (2001). Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clinical Cancer Research, 7(4), 839-845.

Molecular subtypes of anaplastic oligodendroglioma : Implications for patient management at diagnosis. / Ino, Yasushi; Betensky, Rebecca; Zlatescu, Magdalena C.; Sasaki, Hikaru; Macdonald, David R.; Stemmer-Rachamimov, Anat O.; Ramsay, David A.; Cairncross, J. Gregory; Louis, David N.

In: Clinical Cancer Research, Vol. 7, No. 4, 01.01.2001, p. 839-845.

Research output: Contribution to journalArticle

Ino, Y, Betensky, R, Zlatescu, MC, Sasaki, H, Macdonald, DR, Stemmer-Rachamimov, AO, Ramsay, DA, Cairncross, JG & Louis, DN 2001, 'Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis', Clinical Cancer Research, vol. 7, no. 4, pp. 839-845.
Ino Y, Betensky R, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO et al. Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clinical Cancer Research. 2001 Jan 1;7(4):839-845.
Ino, Yasushi ; Betensky, Rebecca ; Zlatescu, Magdalena C. ; Sasaki, Hikaru ; Macdonald, David R. ; Stemmer-Rachamimov, Anat O. ; Ramsay, David A. ; Cairncross, J. Gregory ; Louis, David N. / Molecular subtypes of anaplastic oligodendroglioma : Implications for patient management at diagnosis. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 4. pp. 839-845.
@article{c0b96ad701a1452ca28eaa740112dcb0,
title = "Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis",
abstract = "Purpose: In a prior study of anaplastic oligodendrogliomas treated with chemotherapy at diagnosis or at recurrence after radiotherapy, allelic loss of chromosome 1p correlated with better chemotherapeutic response and overall survival. However, in this group of patients in whom therapeutic management was not uniform, loss of 1p did not identify all chemosensitive tumors, nor did all patients whose tumors harbor a 1p loss have long survival. Experimental Design: To clarify the clinical relevance of molecular genetic testing at the time of diagnosis for patients with anaplastic oligodendrogliomas, we studied a larger, more homogeneous group of 50 patients with histologically defined anaplastic oligodendrogliomas treated with a chemotherapeutic regimen as the principal initial therapy. Results: We demonstrate that these tumors can be divided genetically into four therapeutically and prognostically relevant subgroups. Patients whose tumors have combined but isolated losses of 1p and 19q have marked and durable responses to chemotherapy associated with long survival, with or without postoperative radiation therapy. Other tumors with chromosome 1p alterations also respond to chemotherapy, but with shorter duration of response and patient survival. Tumors lacking 1p loss can also be divided into two subgroups: those with TP53 mutations, which may also respond to chemotherapy but recur quickly, and those without TP53 mutations, which are poorly responsive, aggressive tumors that are clinically and genotypically similar to glioblastomas. Conclusions: These data raise the possibility, for the first time, that therapeutic decisions at the time of diagnosis might be tailored to particular genetic subtypes of anaplastic oligodendroglioma.",
author = "Yasushi Ino and Rebecca Betensky and Zlatescu, {Magdalena C.} and Hikaru Sasaki and Macdonald, {David R.} and Stemmer-Rachamimov, {Anat O.} and Ramsay, {David A.} and Cairncross, {J. Gregory} and Louis, {David N.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "839--845",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Molecular subtypes of anaplastic oligodendroglioma

T2 - Implications for patient management at diagnosis

AU - Ino, Yasushi

AU - Betensky, Rebecca

AU - Zlatescu, Magdalena C.

AU - Sasaki, Hikaru

AU - Macdonald, David R.

AU - Stemmer-Rachamimov, Anat O.

AU - Ramsay, David A.

AU - Cairncross, J. Gregory

AU - Louis, David N.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: In a prior study of anaplastic oligodendrogliomas treated with chemotherapy at diagnosis or at recurrence after radiotherapy, allelic loss of chromosome 1p correlated with better chemotherapeutic response and overall survival. However, in this group of patients in whom therapeutic management was not uniform, loss of 1p did not identify all chemosensitive tumors, nor did all patients whose tumors harbor a 1p loss have long survival. Experimental Design: To clarify the clinical relevance of molecular genetic testing at the time of diagnosis for patients with anaplastic oligodendrogliomas, we studied a larger, more homogeneous group of 50 patients with histologically defined anaplastic oligodendrogliomas treated with a chemotherapeutic regimen as the principal initial therapy. Results: We demonstrate that these tumors can be divided genetically into four therapeutically and prognostically relevant subgroups. Patients whose tumors have combined but isolated losses of 1p and 19q have marked and durable responses to chemotherapy associated with long survival, with or without postoperative radiation therapy. Other tumors with chromosome 1p alterations also respond to chemotherapy, but with shorter duration of response and patient survival. Tumors lacking 1p loss can also be divided into two subgroups: those with TP53 mutations, which may also respond to chemotherapy but recur quickly, and those without TP53 mutations, which are poorly responsive, aggressive tumors that are clinically and genotypically similar to glioblastomas. Conclusions: These data raise the possibility, for the first time, that therapeutic decisions at the time of diagnosis might be tailored to particular genetic subtypes of anaplastic oligodendroglioma.

AB - Purpose: In a prior study of anaplastic oligodendrogliomas treated with chemotherapy at diagnosis or at recurrence after radiotherapy, allelic loss of chromosome 1p correlated with better chemotherapeutic response and overall survival. However, in this group of patients in whom therapeutic management was not uniform, loss of 1p did not identify all chemosensitive tumors, nor did all patients whose tumors harbor a 1p loss have long survival. Experimental Design: To clarify the clinical relevance of molecular genetic testing at the time of diagnosis for patients with anaplastic oligodendrogliomas, we studied a larger, more homogeneous group of 50 patients with histologically defined anaplastic oligodendrogliomas treated with a chemotherapeutic regimen as the principal initial therapy. Results: We demonstrate that these tumors can be divided genetically into four therapeutically and prognostically relevant subgroups. Patients whose tumors have combined but isolated losses of 1p and 19q have marked and durable responses to chemotherapy associated with long survival, with or without postoperative radiation therapy. Other tumors with chromosome 1p alterations also respond to chemotherapy, but with shorter duration of response and patient survival. Tumors lacking 1p loss can also be divided into two subgroups: those with TP53 mutations, which may also respond to chemotherapy but recur quickly, and those without TP53 mutations, which are poorly responsive, aggressive tumors that are clinically and genotypically similar to glioblastomas. Conclusions: These data raise the possibility, for the first time, that therapeutic decisions at the time of diagnosis might be tailored to particular genetic subtypes of anaplastic oligodendroglioma.

UR - http://www.scopus.com/inward/record.url?scp=0034895628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034895628&partnerID=8YFLogxK

M3 - Article

C2 - 11309331

AN - SCOPUS:0034895628

VL - 7

SP - 839

EP - 845

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -